Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of MK-6183 in Renal Impairment
NCT02341599Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2014
- Primary completion
- Apr 2015
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of MK-6183 in Gram-negative bacterial infection (5 arms), sponsored by Merck & Co. Primary endpoints: Area Under the Plasma Concentration-time Curve From Dosing to Last Measurable Concentration, Area Under the Plasma Concentration-time Curve From Dosing to Infinity and 8 more. Started Dec 2014; status: completed.
02
Drugs
MK-6183
03
Conditions
Gram-negative bacterial infection
Beyond the preview
Go deeper on NCT02341599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02341599.